- Home
- GPRK vs FULC Comparison
GPRK vs FULC Comparison
Compare GPRK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- FULC
- Stock Information
- Founded
- GPRK 2002
- FULC 2015
- Country
- GPRK Colombia
- FULC United States
- Employees
- GPRK N/A
- FULC N/A
- Industry
- GPRK Oil & Gas Production
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- FULC Health Care
- Exchange
- GPRK Nasdaq
- FULC Nasdaq
- Market Cap
- GPRK 335.7M
- FULC 372.2M
- IPO Year
- GPRK N/A
- FULC 2019
- Fundamental
- Price
- GPRK $6.35
- FULC $7.66
- Analyst Decision
- GPRK Buy
- FULC Buy
- Analyst Count
- GPRK 1
- FULC 8
- Target Price
- GPRK $11.00
- FULC $7.13
- AVG Volume (30 Days)
- GPRK 704.3K
- FULC 411.3K
- Earning Date
- GPRK 11-05-2025
- FULC 07-29-2025
- Dividend Yield
- GPRK 9.29%
- FULC N/A
- EPS Growth
- GPRK N/A
- FULC N/A
- EPS
- GPRK 0.81
- FULC N/A
- Revenue
- GPRK $560,354,000.00
- FULC N/A
- Revenue This Year
- GPRK N/A
- FULC N/A
- Revenue Next Year
- GPRK N/A
- FULC N/A
- P/E Ratio
- GPRK $7.85
- FULC N/A
- Revenue Growth
- GPRK N/A
- FULC 2752.05
- 52 Week Low
- GPRK $5.66
- FULC $2.32
- 52 Week High
- GPRK $11.72
- FULC $9.30
- Technical
- Relative Strength Index (RSI)
- GPRK 45.00
- FULC 64.62
- Support Level
- GPRK $6.18
- FULC $6.35
- Resistance Level
- GPRK $6.69
- FULC $6.75
- Average True Range (ATR)
- GPRK 0.23
- FULC 0.39
- MACD
- GPRK 0.00
- FULC 0.10
- Stochastic Oscillator
- GPRK 30.00
- FULC 86.18
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.